Overview: Newborn Screening 5 Panel
Introduction: The Newborn Screening 5 Panel is a diagnostic tool designed to screen for newborn metabolic disorders using whole blood samples. In India, adding biotinidase deficiency to TSH, 17-OHP, G6PD, and galactosemia addresses a treatable cause of seizures, rash, alopecia, and developmental delay (prevalence ~1 in 10,000â€"20,000). High morbidity from under-screening in rural/low-SES newborns, limited NBS reach, delayed biotin supplementation leading to irreversible neurological damage. Per pediatrics practices aligned with ICMR, NHM, and RBSK guidelines, the test employs PCR for G6PD deficiency, TSH, 17-OHP, galactosemia, and biotinidase deficiency over 1-2 days with high accuracy, valuable for expanded NBS. This diagnostic falls under newborn screening and targets all newborns, addressing accurate detection to guide biotin therapy and prevent disability. With elevated morbidity due to under-screening, the test supports public health efforts by enabling early intervention and reducing metabolic burden. Its whole blood-based approach ensures reliable multi-disorder detection.
Other Names: NBS 5 Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: Biotinidase added to NBS expansions in India.
Purpose: The test assesses 4 parameters including G6PD deficiency to guide newborn metabolic screening, detect multiple treatable disorders, inform therapy.
Test Parameters: 1. G6PD Deficiency, 2. TSH, 3. 17-OHP, 4. Biotinidase Deficiency.
Pretest Condition: No fasting required; newborns 48-72 hours old preferred.
Specimen: 3 mL whole blood in 1 EDTA tube (heel prick preferred), transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve DNA/hormone integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Parents should provide details on family metabolic history.
Consent: Written parental informed consent is required, detailing the test's purpose, potential risks of untreated disorders including disability, benefits of screening, and minimal discomfort from heel prick.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or prematurity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate treatable metabolic disorders, necessitating specialist input.
Specialist Consultation: Pediatric metabolic specialists should be consulted for management.
Additional Supporting Tests: Serum biotinidase enzyme for confirmation.
Test Limitations: Basic panel only; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, NBS Studies India 2023.
